Länsförsäkringar

Altris specializes in the production of innovative cathode materials for sodium-ion batteries, utilizing abundant and environmentally friendly resources. The company's offerings include highly sustainable, high energy density cathode materials and iron and sodium-based electrodes that are free from nickel, cobalt, and lithium. These materials are designed for rechargeable sodium batteries, which are particularly suitable for stationary energy storage applications. By focusing on the development of safer and more affordable battery solutions, Altris aims to promote the use of environmentally responsible technologies in energy generation and storage.

Wrapp is a rewards application that focuses on enhancing customer loyalty by providing personalized offers and cashback rewards based on users' shopping behaviors. By connecting to users' payment cards, Wrapp analyzes transaction data to deliver relevant rewards from brands that align with consumers' interests, eliminating the need for irrelevant advertisements and outdated membership programs. This approach empowers consumers to gain meaningful rewards while enabling retailers to target their marketing efforts more effectively. Initially, the company operated as a platform for sending digital gift cards, but it has since evolved to prioritize a more personalized and data-driven rewards experience.

Vindmark Group specializes in the manufacturing and sale of innovative wind turbines, utilizing proprietary technology to optimize wind resources that have previously been untapped. The company offers high-quality, cost-effective towers paired with longer rotor blades, catering to both third-party clients and self-financed projects. Vindmark oversees the entire value chain, from initial prospecting through to the construction of wind turbines. By focusing on efficiency and sustainability, Vindmark enables its clients to transition towards renewable energy sources while achieving higher returns on investment and contributing positively to environmental conservation.

Adenovir Pharma AB is a biotechnology company based in Helsingborg, Sweden, focused on developing treatments for infectious diseases affecting the eyes, specifically epidemic keratoconjunctivitis (EKC). Founded in 2008 by researchers from the Department of Virology at Umeå University and P.U.L.S. AB, the company operates within the Medicon Valley, a prominent biotechnology region in Europe. Adenovir Pharma is engaged in the development of a topical antiviral pharmaceutical product aimed at treating and preventing adenoviral conjunctivitis and EKC. The company's initial research has been conducted in collaboration with the University of Lund and external service providers, utilizing unique patented technology and proprietary product concepts. By addressing a significant medical need, Adenovir Pharma seeks to provide effective treatment options for patients and create business development opportunities within the pharmaceutical industry.